Sonal Pruthi1, Ankur Singh2, Chandrawati Kumari3, Ashish Goel4, Seema Kapoor5. 1. Student, University College of Medical Sciences , Delhi, India . 2. Assistant Professor, Department of Paediatrics, Institute of Medical Sciences, Banaras Hindu University , Varanasi, India . 3. PhD Student, Department of Paediatrics, Maulana Azad Medical College , New Delhi, India . 4. Assistant Professor, Department of Medicine, University College of Medical Sciences , Delhi, India . 5. Professor, Department of Pediatrics, Maulana Azad Medical College , New Delhi, India .
Abstract
BACKGROUND: Methyl Malonic Acid (MMA) is known to be an integral component of the cascade of events in mitochondrial energy metabolism and since heart failure involves energy pathways, it is probable that levels of MMA could be used as a reliable biomarker to objectively identify the disease during the early stages and help in prognostication. MATERIALS AND METHODS: The present study was envisaged to evaluate the relation between urinary MMA levels in patients with Ischemic heart disease and in those progressing to failure. The relationship between the severity of the disease and the level of MMA in urine were also evaluated. Analysis of urinary MMA was done by Gas Chromatography-Mass Spectrometry (GC-MS) using stable isotope dilution. Twenty patients each with Ischemic Heart Disease, heart failure and controls were recruited in this pilot study. RESULTS: The mean value of MMA in patients with IHD was 126.71(±66.3) pmol/L and those with IHF was 390.76 (±97.99) pmol/L with the difference being statistically significant (p<0.001). Co-existing B12 deficiency was excluded as that was a potential confounder. CONCLUSION: Levels of MMA were significantly higher in patients with heart failure compared to those with IHF, which were significantly higher than controls. Evaluation of the correlation between MMA levels and the stage of the disease did not reach statistical significance; but this requires adequately powered studies to support this preliminary finding.
BACKGROUND:Methyl Malonic Acid (MMA) is known to be an integral component of the cascade of events in mitochondrial energy metabolism and since heart failure involves energy pathways, it is probable that levels of MMA could be used as a reliable biomarker to objectively identify the disease during the early stages and help in prognostication. MATERIALS AND METHODS: The present study was envisaged to evaluate the relation between urinary MMA levels in patients with Ischemic heart disease and in those progressing to failure. The relationship between the severity of the disease and the level of MMA in urine were also evaluated. Analysis of urinary MMA was done by Gas Chromatography-Mass Spectrometry (GC-MS) using stable isotope dilution. Twenty patients each with Ischemic Heart Disease, heart failure and controls were recruited in this pilot study. RESULTS: The mean value of MMA in patients with IHD was 126.71(±66.3) pmol/L and those with IHF was 390.76 (±97.99) pmol/L with the difference being statistically significant (p<0.001). Co-existing B12 deficiency was excluded as that was a potential confounder. CONCLUSION: Levels of MMA were significantly higher in patients with heart failure compared to those with IHF, which were significantly higher than controls. Evaluation of the correlation between MMA levels and the stage of the disease did not reach statistical significance; but this requires adequately powered studies to support this preliminary finding.
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-12-15 Impact factor: 29.690
Authors: Michael Böhm; Adriaan A Voors; Jean-Marie Ketelslegers; Stephan H Schirmer; Eva Turgonyi; Peter Bramlage; Faiez Zannad Journal: Clin Res Cardiol Date: 2011-07-16 Impact factor: 5.460
Authors: Laurie E Profitlich; Brian Kirmse; Melissa P Wasserstein; George A Diaz; Shubhika Srivastava Journal: Mol Genet Metab Date: 2009-08-12 Impact factor: 4.797